Nephrology Dialysis Transplantation

Article	Citations
COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration	295
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA	246
Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey	134
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls	109
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics	104
European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D	103
ADAM17 inhibition may exert a protective effect on COVID-19	94
How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion	91
Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak	81
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients	81
Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study	77
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)	73
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis	67
Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center	66
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)	64
Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice	62
COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study	61
Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?	61
Targeting acute kidney injury in COVID-19	57
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial	54
Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism	52
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease	52
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort	51
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone	47
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)	46

Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study	45
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disea	44
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAP	44
The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria	44
At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis	44
Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers	42
Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players	41
The impact of chronic kidney disease Stages 3–5 on pregnancy outcomes	41
Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort	40
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results	39
Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management	39
Clinical and predictive value of simplified creatinine index used as muscle mass surrogate in end-stage kidney disease haemodialysis patients—results from the international MONitoring Dialysis Outcome	38
Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?	38
Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study	36
Acute kidney injury and urinary biomarkers in hospitalized patients with coronavirus disease-2019	35
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases	35
Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-19	35
Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa	34
Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS	34
Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease	34
Idiopathic retroperitoneal fibrosis: an update for nephrologists	33
Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study	33
Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease	32
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab	31
How to tackle health literacy problems in chronic kidney disease patients? A systematic review to identify promising intervention targets and strategies	31
Myostatin and muscle atrophy during chronic kidney disease	31
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results	31
SIRT2 is involved in cisplatin-induced acute kidney injury through regulation of mitogen-activated protein kinase phosphatase-1	30
High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients	30
Urine proteomics for prediction of disease progression in patients with IgA nephropathy	30
Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the	30
Impact of first-wave COronaVIrus disease 2019 infection in patients on haemoDIALysis in Alsace: the observational COVIDIAL study	30
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant	29
What should European nephrology do with the new CKD-EPI equation?	29
Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort	29
Tissue sodium concentrations in chronic kidney disease and dialysis patients by lower leg sodium-23 magnetic resonance imaging	29
Contribution of uremic dysbiosis to insulin resistance and sarcopenia	28
Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors	28
Metagenomic profiling of gut microbiome in early chronic kidney disease	28
Acute kidney injury in patients with COVID-19: an update on the pathophysiology	28
Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium	28
Health-related quality of life and symptoms of conservative care versus dialysis in patients with end-stage kidney disease: a systematic review	27
Management of obesity in kidney transplant candidates and recipients: A clinical practice guideline by the DESCARTES Working Group of ERA	26
Measured sodium excretion is associated with CKD progression: results from the KNOW-CKD study	26
Effects of calcitriol and paricalcitol on renal fibrosis in CKD	26
SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions	26
Mapping health-related quality of life after kidney transplantation by group comparisons: a systematic review	26
Tissue sodium stores in peritoneal dialysis and hemodialysis patients determined by sodium-23 magnetic resonance imaging	26
Early versus late acute kidney injury among patients with COVID-19—a multicenter study from Wuhan, China	26
Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?	25

Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients	24
Genetics-first approach improves diagnostics of ESKD patients <50 years old	24
The cholinergic anti-inflammatory pathway in chronic kidney disease—review and vagus nerve stimulation clinical pilot study	24
Renin–angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease	24
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis	24
Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease	24
Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study	23
International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study	23
Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2	23
Kidney disease pathways, options and decisions: an environmental scan of international patient decision aids	23
Dietary plant and animal protein intake and decline in estimated glomerular filtration rate among elderly women: a 10-year longitudinal cohort study	22
Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion	22
Nutritional status, hyperkalaemia and attainment of energy/protein intake targets in haemodialysis patients following plant-based diets: a longitudinal cohort study	22
Hypoxia in chronic kidney disease: towards a paradigm shift?	22
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS	22
Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment	22
Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis	22
Effect of hemodiafiltration on measured physical activity: primary results of the HDFIT randomized controlled trial	22
ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19	21
Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study	21
Magnesium to prevent kidney disease–associated vascular calcification: crystal clear?	21
Persistence of antibody response to SARS-CoV-2 in a cohort of haemodialysis patients with COVID-19	21
Bleeding risk of haemodialysis and peritoneal dialysis patients	20
Early net ultrafiltration rate and mortality in critically ill patients receiving continuous renal replacement therapy	20
Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population	20
Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis	20
Dynapaenia and sarcopaenia in chronic haemodialysis patients: do muscle weakness and atrophy similarly influence poor outcome?	20
Urinary excretion of epidermal growth factor and rapid loss of kidney function	20
Renal transplant outcomes in amyloidosis	20
Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years	20
Young adults have worse kidney transplant outcomes than other age groups	19
Tubulointerstitial nephritis and uveitis syndrome: a systematic review	19
The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation	19
Increasing incidence and improved survival in ANCA-associated vasculitis—a Danish nationwide study	19
The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance	19
Assisted peritoneal dialysis and transfer to haemodialysis: a cause-specific analysis with data from the RDPLF	18
Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals	18
Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection	18
Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry	18
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)	18
Patient-reported factors influencing the choice of their kidney replacement treatment modality	18
Muscle protein turnover and low-protein diets in patients with chronic kidney disease	18
Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults	18
Renal denervation: where do we stand and what is the relevance to the nephrologist?	18
Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia	18
Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials	18
Lactobacillus rhamnosus L34 attenuates chronic kidney disease progression in a 5/6 nephrectomy mouse model through the excretion of anti-inflammatory molecules	18
COVID-19 vaccination in haemodialysis patients: good things come in threes…	17
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials	17
Renal function decline in older men and women with advanced chronic kidney disease—results from the EQUAL study	17
Water intake and progression of chronic kidney disease: the CKD-REIN cohort study	17
Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study	17
The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes	17
COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection	17
Precision medicine approaches for diabetic kidney disease: opportunities and challenges	17
Climate change and nephrology	17
Fibrosis and cancer: shared features and mechanisms suggest common targeted therapeutic approaches	17
Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE	17
The consequences of altered microbiota in immune-related chronic kidney disease	16
Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine	16
Risk factors for venous thromboembolism in patients with nephrotic syndrome: a retrospective cohort study	16
Distal renal tubular acidosis: ERKNet/ESPN clinical practice points	16
Causal effects of physical activity or sedentary behaviors on kidney function: an integrated population-scale observational analysis and Mendelian randomization study	16
Armed conflicts and kidney patients: a consensus statement from the Renal Disaster Relief Task Force of the ERA	16
Factors associated with sex differences in the risk of kidney stones	16
Metabolic dysfunction–associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease	16
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis	16
Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study	16
The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis	16
Peripheral neuropathy: an important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease	15
Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage	15
The clinical characteristics of coronavirus-associated nephropathy	15
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study	15
Precision medicine in Fabry disease	15
Efficacy and safety of combination therapy with sodium–glucose cotransporter 2 inhibitors and renin–angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis	15
Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort	15
Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis	15
Association of subjective global assessment of nutritional status with gut microbiota in hemodialysis patients: a case–control study	15
International peritoneal dialysis training practices and the risk of peritonitis	14
Serum hemoglobin concentration and risk of renal function decline in early stages of diabetic kidney disease: a nationwide, biopsy-based cohort study	14

Phosphoinositide 3-kinase γ deficiency attenuates kidney injury and fibrosis in angiotensin II–induced hypertension	14
LB004A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE	14
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study	14
Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease	14
Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study	14
Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions and relation to morbidity	14
Pre-eclampsia is a valuable opportunity to diagnose chronic kidney disease: a multicentre study	14
Pre-kidney transplant unintentional weight loss leads to worse post-kidney transplant outcomes	14
The Prepare for Kidney Care Study: prepare for renal dialysis versus responsive management in advanced chronic kidney disease	14
Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study	14
Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors	14
Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia	13
CONVINCE in the context of existing evidence on haemodiafiltration	13
Factors influencing fertility rates in Australian women receiving kidney replacement therapy: analysis of linked Australia and New Zealand Dialysis and Transplant Registry and perinatal data over 22 y	13
Long-term risks after kidney donation: how do we inform potential donors? A survey from DESCARTES and EKITA transplantation working groups	13
Survival of patients who opt for dialysis versus conservative care: a systematic review and meta-analysis	13
β-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis	13
Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study	13
Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers	13
Decreased kidney function and agricultural work: a cross-sectional study in middle-aged adults from Tierra Blanca, Mexico	13
Regenerating tubular epithelial cells of the kidney	13
Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease	13
The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification	13
Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort Study	13
Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease	13
DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease	13
Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders	13
Chronic kidney disease, physical activity and cognitive function in older adults—results from the National Health and Nutrition Examination Survey (2011–2014)	13
Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study	12
Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice	12
Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?	12
Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI	12
Long-term outcome of the survivors of infantile hypercalcaemia with CYP24A1 and SLC34A1 mutations	12
Prognostic models for chronic kidney disease: a systematic review and external validation	12
The reasons for a clinical trial on incremental haemodialysis	12
Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis	12
Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease	12
Physical activity and risk of cardiovascular events and all-cause mortality among kidney transplant recipients	12
Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial	12
Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies	12
Laxative use in patients with advanced chronic kidney disease transitioning to dialysis	12
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment	12
Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis	12
Dietary magnesium supplementation inhibits abdominal vascular calcification in an experimental animal model of chronic kidney disease	12
Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease	11
Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis	11
Immune checkpoint inhibitor–associated hypercalcaemia	11
Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database	11
Lessons learned during the war in Ukraine: a report from the Renal Disaster Relief Task Force of the ERA	11
Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial	11
Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic	11
Complement inhibitors for kidney disease	11
Impact of different COVID-19 waves on kidney replacement therapy epidemiology and mortality: REMER 2020	11
Mechanisms of myostatin and activin A accumulation in chronic kidney disease	11
Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease	11
Novel in vitro assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis	11
mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?	11
Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting	11
MO039THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA	11
One concept does not fit all: the immune system in different forms of acute kidney injury	11
C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies	11
Screening of Fabry disease in patients with chronic kidney disease in Japan	11
Drug prescription in patients with chronic kidney disease: a true challenge	11
Association of osteopontin with kidney function and kidney failure in chronic kidney disease patients: the GCKD study	11
Sex difference in ambulatory blood pressure control associates with risk of ESKD and death in CKD patients receiving stable nephrology care	11
Chronic hypoxia exacerbates diabetic glomerulosclerosis through mesangiolysis and podocyte injury in db/db mice	11
Identification of a serum and urine extracellular vesicle signature predicting renal outcome after kidney transplant	11
Can the assessment of ultrasound lung water in haemodialysis patients be simplified?	11
Patterns of renal osteodystrophy 1 year after kidney transplantation	11
Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study	10
Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure	10
Personalizing heart failure management in chronic kidney disease patients	10
Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades	10
Increased risk of ischaemic heart disease after kidney donation	10
Asystole episodes and bradycardia in patients with end-stage renal disease	10
Circulating angiopoietin-2 and angiogenic microRNAs associate with cerebral small vessel disease and cognitive decline in older patients reaching end-stage renal disease	10
Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality	10
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib	10
Recent findings on the clinical utility of renal magnetic resonance imaging biomarkers	10
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab	10
Don’t forget the zinc	10
RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease	10
Itching in dialysis patients: impact on health-related quality of life and interactions with sleep problems and psychological symptoms—results from the RENINE/PROMs registry	10
Barriers to conservative care from patients’ and nephrologists’ perspectives: the CKD-REIN study	10
Temporal trends in the quality of deceased donor kidneys and kidney transplant outcomes in Europe: an analysis by the ERA-EDTA Registry	10
Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s	10
Perspectives on mental health among patients receiving dialysis	10
The problem with transferrin saturation as an indicator of iron ‘sufficiency’ in chronic kidney disease	10
Assessment of a modified renal angina index for AKI prediction in critically ill adults	10
Sodium intake and progression of chronic kidney disease—has the time finally come to do the impossible: a prospective randomized controlled trial?	10
Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy	10
Adding creatinine to routine pregnancy tests: a decision tree for calculating the cost of identifying patients with CKD in pregnancy	10
Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients	10
The incidence and prevalence of IgA nephropathy in Europe	10
Association of single and serial measures of serum phosphorus with adverse outcomes in patients on peritoneal dialysis: results from the international PDOPPS	10